Glucotrol XL is a brand-name medication that contains glipizide as its active ingredient. Glipizide belongs to the sulfonylurea class of oral agents used in diabetes management. In Hong Kong, Glucotrol XL is a prescription-only product and is regulated by the Hong Kong Department of Health.
The medication is supplied as a pill in two strengths: 5 mg and 10 mg. These tablets are designed for once-daily dosing and are intended to help lower elevated blood glucose in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient.
Glipizide stimulates the pancreas to release more insulin. It binds to the sulfonylurea receptor on the ATP-sensitive potassium (K-ATP) channel of pancreatic β-cells, causing the channel to close. This leads to cell depolarization, calcium influx, and ultimately increased insulin secretion. The result is a reduction in fasting and post-prandial blood glucose levels.
By enhancing endogenous insulin, glipizide helps improve glucose uptake by peripheral tissues.
Glucotrol XL is approved in Hong Kong for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet, exercise, and other glucose-lowering therapies when needed. It is not indicated for type 1 diabetes, gestational diabetes, or diabetic ketoacidosis.
Typical patients who benefit include those:
If any of these conditions apply, a healthcare provider should assess the risk-benefit balance before prescribing Glucotrol XL.
These effects are usually transient and may lessen with continued therapy.
If any serious reaction occurs, seek immediate medical attention.
Patients should disclose all prescription medicines, over-the-counter products, and herbal supplements to their prescriber.
All dosing decisions must be individualized by a qualified healthcare professional.
Patients should promptly report any episodes of unexplained hypoglycemia or new symptoms.
If a tablet becomes damaged or discolored, discard it according to local pharmaceutical waste guidelines.
This article provides educational information about Glucotrol XL and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Glucotrol XL can be combined with metformin, thiazolidinediones, or DPP-4 inhibitors when a single agent does not achieve target glucose levels. The combination should be prescribed by a clinician who can monitor for additive hypoglycemia risk.
Glipizide primarily influences glucose metabolism and has minimal direct effects on lipid profiles or blood pressure. Any observed changes are usually indirect, reflecting improved glycemic control.
Take the missed tablet as soon as you remember, provided it is at least 8 hours before the next scheduled dose. Otherwise, skip the missed dose and resume your regular dosing schedule to avoid double dosing.
Both strengths are round, film-coated pills, but the 10 mg tablet is typically larger and may have a distinct imprint code (e.g., “GLX 10”) to help differentiate it from the 5 mg version.
Glipizide is not a controlled substance and is not screened for in standard workplace drug tests. However, occupational health policies vary, so confirm with the employer if needed.
Moderate alcohol consumption can increase the risk of hypoglycemia, especially when taken on an empty stomach. Limit intake and monitor blood glucose closely after drinking.
For patients with eGFR 30-50 mL/min/1.73 m², clinicians often start at the lowest dose (5 mg) and may avoid increasing beyond that unless glucose remains uncontrolled. Renal function should be re-checked regularly.
Glipizide generally has a shorter half-life and a lower risk of prolonged hypoglycemia compared with some longer-acting sulfonylureas. Choice of agent depends on patient-specific factors and physician preference.
If a tablet fragments, discard it and use an intact tablet. Splitting is not recommended for Glucotrol XL because the extended-release formulation may not distribute evenly.
Glucotrol XL is contraindicated in pregnancy because sulfonylureas cross the placenta and may cause fetal hypoglycemia. Pregnant patients should discuss alternative insulin-based therapies with their obstetrician.
